APUS Apimeds Pharmaceuticals US, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1894525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-341.0%
TTM EPS YoY-84.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-30.6%
ROA-27.9%
ROIC (approx.)-26.2%
Asset turnover—
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio0.83x
Interest coverage-4.35x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $2.90M | $282,732 | — | — | — | — | — | — |
| Cost of revenue | $54,300 | — | — | — | — | — | — | — |
| Gross profit | $2.84M | — | — | — | — | — | — | — |
| R&D expense | — | $959,742 | $901,144 | $361,104 | $619,693 | $651,784 | — | — |
| SG&A expense | $814,477 | $5.32M | $11.28M | $6.68M | $1.22M | $2.01M | $364,368 | $275,613 |
| Operating income | $2.03M | -$6.28M | -$12.19M | -$7.04M | -$1.84M | -$2.66M | -$364,368 | -$275,613 |
| Interest expense | $1.09M | $3.22M | $859,405 | $215,624 | $6,301 | $23,054 | $38,032 | $36,050 |
| Net income | $33.65M | -$20.17M | -$35.06M | -$1.16M | -$1.78M | -$2.66M | -$402,397 | -$311,633 |
| EBITDA | $2.03M | -$6.27M | -$12.17M | -$7.04M | -$1.84M | -$2.66M | — | — |
| EPS (basic) | 19.13 | -11.77 | -2.26 | — | -1.42 | -2.57 | -0.05 | — |
| EPS (diluted) | 7.68 | -11.77 | -2.26 | — | -1.42 | -2.57 | -0.05 | — |
| Weighted avg. shares (diluted) | 4.48M | 1.71M | 15.51M | — | 1.26M | 1.04M | 7.90M | — |
| Banking | ||||||||
| Deposits | — | — | — | $8.00M | — | — | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $17,912 | $278,371 | $979,534 | $144,601 | $6.99M | $8.74M | $250,432 | $3,455 |
| Short-term investments | — | — | $1.50M | $2.00M | — | — | — | — |
| Receivables | $2.48M | — | — | — | — | — | — | — |
| Current assets | $10.85M | $10.68M | $13.15M | $13.98M | $9.09M | $10.35M | $259,904 | $13,057 |
| PP&E, net | — | $51,929 | $56,592 | $51,626 | $34,188 | $13,137 | — | — |
| Total assets | $153.53M | $127.62M | $141.22M | $164.18M | $9.25M | $10.55M | $259,904 | $13,057 |
| Current liabilities | $13.01M | $21.07M | $14.58M | $10.71M | $1.09M | $809,002 | $1.77M | $1.02M |
| Total liabilities | $13.01M | $21.18M | $14.70M | $10.84M | $1.09M | $809,002 | $2.02M | $1.37M |
| Shareholders' equity | $140.52M | $106.45M | $126.52M | $153.35M | $8.16M | $9.74M | -$1.76M | -$1.36M |
| Shares outstanding | 1.85M | 1.51M | 12.58M | 1.26M | 12.58M | 12.58M | 7.90M | 7.90M |
| Cash flow statement | ||||||||
| Operating cash flow | -$218,617 | -$5.67M | -$2.07M | -$3.82M | -$1.73M | -$3.36M | -$20,313 | -$99,616 |
| Capital expenditure | $0 | $0 | $9,394 | $21,424 | $22,540 | — | — | — |
| Free cash flow | -$218,617 | -$5.67M | -$2.08M | -$3.84M | -$1.75M | — | — | — |
| Investing cash flow | -$53,186 | $1.50M | $490,606 | -$10.02M | -$22,540 | — | — | — |
| Financing cash flow | $11,345 | $3.47M | $920,000 | $8.49M | $0 | $11.86M | $267,200 | $76,500 |
| Depreciation & amortization | $0 | $4,662 | $20,044 | $3,985 | $1,489 | $232 | — | — |
| Stock-based compensation | -$1,051 | $105,210 | — | $1.33M | $42,674 | $192,053 | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.